36.57 MW solar + wind captive renewable portfolio Company has invested ₹161.06 crores in setting-up solar/wind renewable energy power plants at Solapur (Maharashtra), Patan (Gujarat), Khandwa (M.P.) and Athal (Silvassa) with total capacity of 36.57 MW till March 31, 2025. Includes 20 MW solar power plant at Khandwa, Madhya Pradesh feeding captive consumption. During FY24-25 these power plants generated 319.81 lac (31.98 million) kWh. Nearly 10% of Company's electricity requirement is supported by Company's own captive solar plants. Company also amended MoA to enable setting up of captive power generation projects from conventional and renewable energy sources.
▾ expand
20% Scope 1+2 reduction target by 2030 Company has set a target of 20% reduction in carbon emissions (Scope 1 and 2) by 2030. Reported 5.57% reduction in Scope 1+2 vs previous year. No baseline year explicitly specified.
▾ expand
35% hazardous waste co-processing by 2030 Target to dispose 35% of hazardous waste through co-processing by 2030. Achieved 19% in FY24-25.
▾ expand
20% women in office workforce by 2030 Diversity target: 20% of women employees in offices by 2030. Achieved 20.21% in FY24-25 - target met.
▾ expand
100% critical suppliers compliant with sustainable procurement by 2030 Target for 100% of critical suppliers to be compliant with the Sustainable Procurement Policy by 2030. Self-Assessment Questionnaire floated to critical Raw Material and Packaging Material suppliers.
▾ expand
BRSR Core reasonable assurance + limited for rest by SGS India SGS India Private Limited provided reasonable assurance on BRSR Core indicators (9 ESG attributes) and limited assurance on remaining BRSR parameters for FY24-25. This is mandated under SEBI BRSR Core framework.
▾ expand
Sale of Tarapur formulations manufacturing facility Company signed agreement to sell its formulations manufacturing facility at T-139, MIDC, Tarapur on slump sale basis for ₹36.90 crores. Assets reclassified as held for sale. Part of operational consolidation strategy to reduce manufacturing units.
▾ expand
New mAbs, Drug Intermediates and Formulation manufacturing units Company is setting up new green field facilities: Drug Intermediates plant at Hingni Wardha (₹150 cr), formulations plant at Dewas (₹275 cr), Monoclonal Antibodies (mAbs) facility at Pithampur (₹250 cr), and liquid injectables/oral liquids at Pisgah Forest USA (USD 20m).
▾ expand
Memorandum altered to permit captive power generation Special resolution proposed to amend Memorandum and Articles of Association to permit setting up of captive power generation projects including from renewable sources (solar, wind, geothermal, tidal) to enable grant of captive status for the existing 20 MW Khandwa solar plant in Madhya Pradesh.
▾ expand
ISO 14001 & ISO 45001 certifications at multiple sites Four API sites and two formulations sites are certified under ISO 45001. ISO 14001 environmental management standard adopted alongside cGMP. Subject to regular surveillance and re-certification audits by third party.
▾ expand
see 21 more events →